



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

SI-2 hydrochloride

Cat. No.:	HY-101447A
CAS No.:	1992052-49-9
Molecular Formula:	C ₁₅ H ₁₆ ClN ₅
Molecular Weight:	301.77
Target:	Others
Pathway:	Others
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



HCl

SOLVENT & SOLUBILITY

In Vitro	DMSO : 5 mg/mL (16.57 mM; Need ultrasonic)				
	Preparing Stock Solutions	<div> <div>Solvent</div> <div>Concentration</div> <div>Mass</div> </div>	1 mg	5 mg	10 mg
			3.3138 mL	16.5689 mL	33.1378 mL
			0.6628 mL	3.3138 mL	6.6276 mL
			0.3314 mL	1.6569 mL	3.3138 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	SI-2 (EPH 116 hydrochloride) is a highly promising SRC-3 inhibitor (PPI), with IC ₅₀ values of 3-20 nM for breast cancer cell death. SI-2 (EPH 116 hydrochloride) has a much improved toxicity and pharmacokinetic profile, with acceptable oral availability ^[1] .	
IC ₅₀ & Target	IC ₅₀ 3-20 nM (breast cancer cell death) ^[1] .	
In Vitro	SI-2 selectively reduce the transcriptional activities and the protein concentrations of SRC-3 in cells through direct physical interactions with SRC-3 ^[1] . ?SI-2 selectively induces breast cancer cell death with IC ₅₀ values in the low nanomolar range (3-20 nM), but not affect normal cell viability ^[1] . ?SI-2 (100 nM) decreases cell motility, invasion, and tumor metastasis in MDAMB-468 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[1] .	
	Cell Line:	MDA-MB-468 cells.

Concentration:	100 nM.
Incubation Time:	12 hours.
Result:	Significantly reduced the motility of cancer cells.
Western Blot Analysis ^[1] .	
Cell Line:	MDAMB-468 cells.
Concentration:	0-200 nM.
Incubation Time:	24 hours.
Result:	Significantly reduced SRC-3 protein levels. Did not decrease the SRC-3 mRNA level.
Western Blot Analysis ^[1] .	
Cell Line:	Cancer cells.
Concentration:	0-200 nM.
Incubation Time:	24 hours.
Result:	Caused PARP cleavage.

In Vivo

SI-2 causes minimal acute cardiotoxicity based on a hERG channel blocking assay and an unappreciable chronic toxicity to major organs based on histological analyses^[1].
 ?SI-2 is a drug-like molecule and meets all of the criteria of Lipinski's rule^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MDA-MB-468 breast cancer mouse model ^[1] .
Dosage:	2 mg/kg.
Administration:	Twice daily for 5 weeks (Vehicle, PBS).
Result:	Significantly inhibit tumor growth. SRC-3 levels in SI-2-treated tumor tissues were significantly lower than the PBS treated control group.
Animal Model:	CD1 mice ^[1] .
Dosage:	20 mg/kg (Pharmacokinetic Analysis).
Administration:	Intraperitoneal administration once.
Result:	T _{1/2} = 1 h, C _{max} of 3.0 μM, and the time to reach the maximum plasma concentration t _{max} of 0.25 h. SI-2 only degrades slightly (less than 5%) at pH 1.6 and 3.0 within 6 h, and is stable in buffers with pH ≥ 5.

REFERENCES

[1]. Song X, et al. Development of potent small-molecule inhibitors to drug the undruggable steroid receptor coactivator-3. Proc Natl Acad Sci U S A. 2016 May 3;113(18):4970-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA